How it works

After 40, your cells produce less NAD+—a coenzyme that sits at the center of energy metabolism and DNA repair. Think of NAD+ as the cellular currency your mitochondria and repair enzymes spend to keep you functional. NMN (nicotinamide mononucleotide) is a direct precursor that enters the NAD+ biosynthesis pathway via the enzyme NAMPT, bypassing the slower, less efficient steps that degrade with age. Resveratrol's role is distinct but complementary: it acts as a SIRT1 activator, essentially turning up the dial on a class of longevity-associated enzymes that only work when NAD+ is present. Neither compound is a shortcut. Together, they address two interdependent bottlenecks—substrate availability and enzymatic activity—that accumulate over decades of normal aging.

• NMN enters cells via the Slc12a8 transporter and is phosphorylated to NAD+ within minutes; plasma half-life is approximately 2–3 hours, which is why consistent daily dosing matters more than sporadic high doses.
• NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, declines with age and chronic inflammation; NMN supplementation effectively bypasses this enzymatic bottleneck by delivering the substrate downstream of NAMPT.
• Sirtuins (SIRT1–SIRT7) are NAD+-dependent deacylases that regulate mitochondrial biogenesis, circadian rhythm entrainment, and histone deacetylation; they consume NAD+ stoichiometrically, so low NAD+ floors functionally silence sirtuin activity regardless of gene expression.
• Trans-resveratrol binds SIRT1 at an allosteric site, lowering the Km for NAD+ and effectively making the enzyme more active at physiological NAD+ concentrations; this synergy means resveratrol's benefit is mechanistically contingent on adequate NAD+ availability.
• Downstream of SIRT1 activation, PGC-1α is deacetylated and activated, initiating a transcriptional cascade that upregulates mitochondrial biogenesis, fatty acid oxidation, and antioxidant defense via NRF2—pathways measurable through VO2 max trends and fasting glucose variability.

The evidence

The honest summary: the mechanistic case for NMN and resveratrol is robust at the cellular and animal level, and human trials conducted since 2020 are beginning to validate physiologically relevant endpoints—muscle insulin sensitivity, arterial stiffness, and walking speed in older adults. This is not yet the evidence base of a statin or metformin. Extrapolation from mouse lifespan studies to human longevity is premature. What we can say with reasonable confidence is that NAD+ precursor supplementation raises blood NAD+ levels in humans, and that this biochemical change is associated with markers the longevity field considers meaningful. We present the evidence as it stands—promising, directional, and still accumulating.

How we dose it

Stacks well with

• Taurine (1–2g/day): emerging evidence from Zhang et al. 2023 (Science) suggests taurine deficiency is a driver of aging hallmarks; mechanistically orthogonal to the NAD+ pathway, making it additive rather than redundant.
• Magnesium glycinate (200–400mg/night): magnesium is a cofactor for over 300 enzymatic reactions including ATP synthesis; deficiency blunts mitochondrial efficiency and impairs the downstream energy output that NAD+ repletion is meant to support.
• Morning sunlight exposure (10–20 minutes): anchors the circadian clock via retinal ipRGC signaling, which directly regulates NAMPT transcription through CLOCK/BMAL1—reinforcing the biochemical environment in which this stack operates.

Avoid with

• High-dose niacin (nicotinamide/niacinamide above 500mg/day): competes with NMN at the NAD+ salvage pathway and may paradoxically suppress SIRT1 activity through nicotinamide feedback inhibition; do not co-administer.
• Broad-spectrum antibiotics: gut microbiome composition influences NMN absorption and NAD+ precursor metabolism; if a course of antibiotics is necessary, consider pausing this stack and prioritizing microbiome restoration before resuming.

Who it's for

This protocol is designed for adults aged 40–65 who are already managing the fundamentals—sleep, training, nutrition—and are now looking to address the biochemical underpinnings of cellular aging with the same rigor they apply to everything else. It is for people who read primary literature, track biomarkers, and are appropriately skeptical of supplement marketing while remaining open to evidence-informed intervention.

1. Age 48. Maintain VO2 max and muscle insulin sensitivity through perimenopause without pharmaceutical intervention Tracking: Fasting glucose trending toward 95–99 mg/dL; VO2 max declining 3–5% per year despite consistent training.
2. Age 55. Slow biological age progression as measured by epigenetic clocks while optimizing cognitive throughput for a demanding executive schedule Tracking: GrimAge or DunedinPACE score above chronological age; HRV declining year-over-year.
3. Age 62. Support mitochondrial density and arterial compliance as a foundation for a decade-long healthspan extension strategy Tracking: Pulse wave velocity or coronary artery calcium score; skeletal muscle mass by DEXA declining.

What to expect

• Weeks 1-2: Most users report no dramatic subjective change in the first two weeks—this is expected and appropriate; the protocol is working at the enzymatic and metabolic level, not via stimulant mechanisms, and any immediate perceived energy shift is likely circadian or placebo in origin.
• Weeks 3-6: Anecdotally and consistent with some trial data, users begin reporting improved sleep quality, more stable energy across the afternoon, and reduced subjective recovery time after exercise—correlating with the timeframe in which measurable NAD+ elevation has been confirmed in blood.
• Weeks 8-12: The biomarker window: if you are tracking fasting glucose, HbA1c, or running aerobic capacity tests, weeks 8–12 represent the earliest meaningful checkpoint; some users see modest improvements in HOMA-IR, resting heart rate, and subjective cognitive clarity that were not present at baseline.

Biomarkers to track

• Whole-blood NAD+ levels (available through specialized labs such as Jinfiniti Precision Medicine; baseline before starting, retest at 8–12 weeks)
• Fasting glucose and HOMA-IR (standard metabolic panel; sensitive to the insulin-signaling effects observed in the Yoshino 2021 trial)
• Heart rate variability (HRV) via daily wearable tracking; reflects autonomic nervous system recovery and mitochondrial efficiency over time

How we compare

Questions